Royal Bank of Canada’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.25M | Buy |
90,387
+630
| +0.7% | +$29K | ﹤0.01% | 2379 |
|
|
2025
Q4 | $4.02M | Sell |
89,757
-30,788
| -26% | -$1.29M | ﹤0.01% | 2598 |
|
|
2025
Q3 | $4.84M | Sell |
120,545
-26,681
| -18% | -$940K | ﹤0.01% | 2705 |
|
|
2025
Q2 | $4.61M | Buy |
147,226
+87,860
| +148% | +$2.87M | ﹤0.01% | 2635 |
|
|
2025
Q1 | $1.99M | Sell |
59,366
-702
| -1% | -$26.7K | ﹤0.01% | 2950 |
|
|
2024
Q4 | $2.35M | Buy |
60,068
+22,432
| +60% | +$927K | ﹤0.01% | 2913 |
|
|
2024
Q3 | $1.48M | Buy |
37,636
+1,248
| +3% | +$50.3K | ﹤0.01% | 3225 |
|
|
2024
Q2 | $1.42M | Buy |
36,388
+1,256
| +4% | +$50.2K | ﹤0.01% | 3170 |
|
|
2024
Q1 | $1.51M | Sell |
35,132
-923
| -3% | -$42.5K | ﹤0.01% | 3140 |
|
|
2023
Q4 | $1.66M | Buy |
36,055
+8,934
| +33% | +$316K | ﹤0.01% | 3223 |
|
|
2023
Q3 | $927K | Buy |
27,121
+2,920
| +12% | +$109K | ﹤0.01% | 3500 |
|
|
2023
Q2 | $932K | Buy |
24,201
+11,717
| +94% | +$466K | ﹤0.01% | 3426 |
|
|
2023
Q1 | $447K | Sell |
12,484
-3,646
| -23% | -$135K | ﹤0.01% | 3955 |
|
|
2022
Q4 | $636K | Buy |
16,130
+16,129
| +1,612,900% | +$587K | ﹤0.01% | 3883 |
|
|
2022
Q3 | $0 | Buy |
+1
| New | +$36 | ﹤0.01% | 7934 |
|
|
2022
Q2 | – | Sell |
-24,313
| Closed | -$743K | – | 7763 |
|
|
2022
Q1 | $743K | Hold |
24,313
| – | – | ﹤0.01% | 3924 |
|
|
2021
Q4 | $760K | Sell |
24,313
-1,000
| -4% | -$29.9K | ﹤0.01% | 4090 |
|
|
2021
Q3 | $387K | Sell |
25,313
-57
| -0.2% | -$990 | ﹤0.01% | 4563 |
|
|
2021
Q2 | $472K | Hold |
25,370
| – | – | ﹤0.01% | 4340 |
|
|
2021
Q1 | $454K | Sell |
25,370
-15,513
| -38% | -$263K | ﹤0.01% | 4274 |
|
|
2020
Q4 | $629K | Buy |
40,883
+57
| +0.1% | +$667 | ﹤0.01% | 3935 |
|
|
2020
Q3 | $452K | Hold |
40,826
| – | – | ﹤0.01% | 3945 |
|
|
2020
Q2 | $512K | Sell |
40,826
-188
| -0.5% | -$2.39K | ﹤0.01% | 3751 |
|
|
2020
Q1 | $465K | Sell |
41,014
-5,558
| -12% | -$79.2K | ﹤0.01% | 3682 |
|
|
2019
Q4 | $611K | Sell |
46,572
-35,790
| -43% | -$376K | ﹤0.01% | 3833 |
|
|
2019
Q3 | $742K | Buy |
82,362
+22,022
| +36% | +$208K | ﹤0.01% | 3570 |
|
|
2019
Q2 | $595K | Buy |
60,340
+3,302
| +6% | +$31.6K | ﹤0.01% | 3735 |
|
|
2019
Q1 | $580K | Buy |
57,038
+492
| +0.9% | +$4.17K | ﹤0.01% | 3636 |
|
|
2018
Q4 | $357K | Sell |
56,546
-32,146
| -36% | -$286K | ﹤0.01% | 3946 |
|
|
2018
Q3 | $1.17M | Sell |
88,692
-28,000
| -24% | -$324K | ﹤0.01% | 3239 |
|
|
2018
Q2 | $1.07M | Hold |
116,692
| – | – | ﹤0.01% | 3177 |
|
|
2018
Q1 | $572K | Hold |
116,692
| – | – | ﹤0.01% | 3611 |
|
|
2017
Q4 | $330K | Buy |
116,692
+75,519
| +183% | +$205K | ﹤0.01% | 4101 |
|
|
2017
Q3 | $121K | Sell |
41,173
-15,000
| -27% | -$46.4K | ﹤0.01% | 4871 |
|
|
2017
Q2 | $177K | Hold |
56,173
| – | – | ﹤0.01% | 4434 |
|
|
2017
Q1 | $225K | Sell |
56,173
-190,104
| -77% | -$1.49M | ﹤0.01% | 4274 |
|
|
2016
Q4 | $1.9M | Sell |
246,277
-121,034
| -33% | -$972K | ﹤0.01% | 2633 |
|
|
2016
Q3 | $2.98M | Sell |
367,311
-25,173
| -6% | -$194K | ﹤0.01% | 2272 |
|
|
2016
Q2 | $2.31M | Sell |
392,484
-75,519
| -16% | -$518K | ﹤0.01% | 2422 |
|
|
2016
Q1 | $3.27M | Sell |
468,003
-286
| -0.1% | -$2.06K | ﹤0.01% | 2097 |
|
|
2015
Q4 | $3.77M | Hold |
468,289
| – | – | ﹤0.01% | 2044 |
|
|
2015
Q3 | $3.87M | Buy |
468,289
+1,286
| +0.3% | +$12.8K | ﹤0.01% | 1746 |
|
|
2015
Q2 | $5.38M | Buy |
467,003
+136,801
| +41% | +$1.89M | ﹤0.01% | 1556 |
|
|
2015
Q1 | $5.57M | Buy |
330,202
+229,510
| +228% | +$4.24M | ﹤0.01% | 1535 |
|
|
2014
Q4 | $1.99M | Buy |
+100,692
| New | +$1.48M | ﹤0.01% | 2335 |
|
Other funds holding XENE
ACA
DCM
PCH
Royal Bank of Canada's XENE Position: Q1 2026 in Review
Royal Bank of Canada increased its Xenon Pharmaceuticals (XENE) stake by 0.7% in Q1 2026, buying an estimated $29K and bringing the position to 90,387 shares worth $5.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2379.
Royal Bank of Canada first reported a position in XENE in Q4 2014 and has held it in 45 quarters since. The position peaked at $5.57M in Q1 2015. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.
- Royal Bank of Canada held 90,387 shares of Xenon Pharmaceuticals worth $5.25M as of Q1 2026.
- Royal Bank of Canada bought 630 Xenon Pharmaceuticals shares in Q1 2026, an estimated $29K.
- Xenon Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #2379 holding.
- Royal Bank of Canada first reported a position in Xenon Pharmaceuticals in Q4 2014 and has held it in 45 quarters since.
- Royal Bank of Canada's Xenon Pharmaceuticals position peaked at $5.57M in Q1 2015.
- 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.